Alpha Cubed Investments LLC Sells 3,270 Shares of Amgen Inc. $AMGN

Key Points

• Alpha Cubed Investments LLC trimmed its stake in Amgen by 20.5%, selling 3,270 shares and leaving it with 12,659 shares valued at about $4.14 million.
• Amgen beat quarterly estimates with $5.15 EPS vs. $4.77 expected and revenue of $8.62 billion, and set FY 2026 guidance of 21.70–23.10 EPS (consensus ~22.45).
• The company declared a quarterly dividend of $2.52 per share (annualized $10.08, ~3.1% yield), with an ex‑dividend/record date of May 15 and payment on June 5.

Alpha Cubed Investments LLC trimmed its stake in shares of Amgen Inc. (NASDAQ:AMGN - Free Report) by 20.5% in the fourth quarter, according to the company in its most recent filing with the SEC. The firm owned 12,659 shares of the medical research company's stock after selling 3,270 shares during the quarter. Alpha Cubed Investments LLC's holdings in Amgen were worth $4,144,000 as of its most recent SEC filing.

A number of other institutional investors have also recently modified their holdings of the stock. Vanguard Group Inc. lifted its position in shares of Amgen by 1.8% during the 4th quarter. Vanguard Group Inc. now owns 54,838,826 shares of the medical research company's stock valued at $17,949,296,000 after acquiring an additional 961,975 shares during the period. Capital International Investors lifted its position in shares of Amgen by 1.5% during the 3rd quarter. Capital International Investors now owns 19,192,995 shares of the medical research company's stock worth $5,414,296,000 after buying an additional 282,219 shares during the last quarter. Capital World Investors lifted its position in shares of Amgen by 11.5% during the 3rd quarter. Capital World Investors now owns 18,795,474 shares of the medical research company's stock worth $5,303,578,000 after buying an additional 1,935,876 shares during the last quarter. Capital Research Global Investors lifted its position in shares of Amgen by 2.7% during the 3rd quarter. Capital Research Global Investors now owns 4,731,290 shares of the medical research company's stock worth $1,335,168,000 after buying an additional 122,631 shares during the last quarter. Finally, Invesco Ltd. lifted its position in shares of Amgen by 6.6% during the 3rd quarter. Invesco Ltd. now owns 4,467,287 shares of the medical research company's stock worth $1,260,668,000 after buying an additional 277,031 shares during the last quarter. 76.50% of the stock is currently owned by institutional investors.

Amgen Price Performance

Shares of AMGN opened at $329.59 on Wednesday. Amgen Inc. has a 1 year low of $261.43 and a 1 year high of $391.29. The company has a debt-to-equity ratio of 5.65, a current ratio of 1.26 and a quick ratio of 0.90. The company has a market capitalization of $177.87 billion, a price-to-earnings ratio of 22.94, a price-to-earnings-growth ratio of 3.08 and a beta of 0.44. The business has a 50-day moving average of $357.16 and a 200-day moving average of $341.35.

Amgen (NASDAQ:AMGN - Get Free Report) last issued its quarterly earnings data on Thursday, April 30th. The medical research company reported $5.15 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $4.77 by $0.38. Amgen had a return on equity of 137.41% and a net margin of 20.96%.The company had revenue of $8.62 billion during the quarter, compared to the consensus estimate of $8.58 billion. During the same period last year, the company earned $4.90 earnings per share. The firm's revenue was up 5.8% compared to the same quarter last year. Amgen has set its FY 2026 guidance at 21.700-23.100 EPS. As a group, equities research analysts anticipate that Amgen Inc. will post 22.45 earnings per share for the current year.

Amgen Dividend Announcement

The firm also recently announced a quarterly dividend, which will be paid on Friday, June 5th. Investors of record on Friday, May 15th will be paid a dividend of $2.52 per share. The ex-dividend date of this dividend is Friday, May 15th. This represents a $10.08 annualized dividend and a yield of 3.1%. Amgen's dividend payout ratio (DPR) is currently 70.15%.

Insider Buying and Selling

In related news, SVP Nancy A. Grygiel sold 1,237 shares of the firm's stock in a transaction that occurred on Monday, May 4th. The stock was sold at an average price of $323.73, for a total transaction of $400,454.01. Following the completion of the sale, the senior vice president owned 7,009 shares of the company's stock, valued at $2,269,023.57. This trade represents a 15.00% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. 0.85% of the stock is owned by corporate insiders.

Amgen News Summary

Here are the key news stories impacting Amgen this week:

• Positive Sentiment: Amgen announced a $300 million additional U.S. manufacturing investment (Puerto Rico) to expand biologics capacity and strengthen supply-chain resilience; investors tend to see such capital spending as supportive of long-term growth and reliability. Article Title
• Neutral Sentiment: Erste Group reaffirmed a "hold" rating on AMGN, signaling no change in near-term analyst conviction and limiting directional impact from that broker. Article Title
• Neutral Sentiment: Market/sector headwinds: healthcare stocks were softer in recent trading sessions, a background factor that can mute upside for AMGN even as company-specific news emerges. Article Title
• Negative Sentiment: Competitive risk: Viridian Therapeutics reported encouraging results for its chronic thyroid eye disease program, a potential rival to Amgen’s Tepezza — the data lifted Viridian shares and raises the probability of increased market competition for Tepezza sales over time. Article Title
• Negative Sentiment: Guggenheim trimmed its price target on AMGN to $340 (from $351) while keeping a Neutral rating — a modest lowering of upside that can cap near-term analyst-driven buying. Article Title

Wall Street Analysts Forecast Growth

Several brokerages recently weighed in on AMGN. Argus upped their price objective on Amgen from $360.00 to $400.00 and gave the stock a "buy" rating in a research report on Friday, February 6th. Canaccord Genuity Group assumed coverage on Amgen in a report on Monday, April 20th. They issued a "hold" rating and a $366.00 target price for the company. Sanford C. Bernstein cut Amgen from an "outperform" rating to a "market perform" rating and set a $335.00 target price for the company. in a report on Tuesday, January 20th. Royal Bank Of Canada upped their target price on Amgen from $360.00 to $370.00 and gave the stock an "outperform" rating in a report on Tuesday, April 7th. Finally, Guggenheim decreased their price objective on Amgen from $351.00 to $340.00 and set a "neutral" rating for the company in a report on Monday. One equities research analyst has rated the stock with a Strong Buy rating, thirteen have given a Buy rating, fifteen have issued a Hold rating and two have given a Sell rating to the company's stock. According to data from MarketBeat, the stock currently has an average rating of "Hold" and a consensus target price of $357.12.

About Amgen

Amgen Inc NASDAQ: AMGN is a global biotechnology company founded in 1980 and headquartered in Thousand Oaks, California. The company focuses on discovering, developing, manufacturing and delivering human therapeutics that address serious illnesses. Amgen's work centers on biologic medicines derived from cellular and molecular biology, with an emphasis on translating advances in human genetics and protein science into therapies for patients.

Amgen's commercial portfolio has historically included biologics used in oncology, supportive care, nephrology, bone health and cardiovascular disease.

Want to see what other hedge funds are holding AMGN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Amgen Inc. (NASDAQ:AMGN - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.